File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Arsenates in the treatment of haematological malignancies

TitleArsenates in the treatment of haematological malignancies
Authors
KeywordsArsenic trioxide
Intravenous
Oral
Acute promyelocytic leukemia
Side effects
Issue Date2004
PublisherWorld Scientific Publishing Co Pte Ltd. The Journal's web site is located at http://www.worldscinet.com/cr/cr.shtml
Citation
Cancer Reviews: Asia-Pacific, 2004, v. 2 n. 2, p. 161-171 How to Cite?
AbstractArsenic trioxide (As2O3) for leukemia treatment has been known for over a century. The recent rekindling of the interest in As2O3 is due to its high efficacy in acute promyelocytic leukemia (APL), inducing remissions in over 90% of newly diagnosed or relapsed cases. Most As2O3 preparations are intravenous, although an oral formulation is similarly efficacious. Important side effects include prolongation of QT interval, leucocytosis and the APL differentiation syndrome. Combined use of As2O3 and all trans-retinoic acid (ATRA) has been found to be useful in APL relapsing from previous arsenic-induced remissions. Furthermore, As2O3 + ATRA may give remissions of better quality in newly diagnosed APL. Current research centers on the early introduction of As2O3 in the overall treatment plan of APL, including its use in maintenance therapy after first complete remission. As2O3 has also been used in other hematological malignancies. Of particular promise is the use of As2O3 in multiple myeloma.
Persistent Identifierhttp://hdl.handle.net/10722/76396
ISSN

 

DC FieldValueLanguage
dc.contributor.authorKwong, YL-
dc.date.accessioned2010-09-06T07:20:46Z-
dc.date.available2010-09-06T07:20:46Z-
dc.date.issued2004-
dc.identifier.citationCancer Reviews: Asia-Pacific, 2004, v. 2 n. 2, p. 161-171-
dc.identifier.issn0219-8363-
dc.identifier.urihttp://hdl.handle.net/10722/76396-
dc.description.abstractArsenic trioxide (As2O3) for leukemia treatment has been known for over a century. The recent rekindling of the interest in As2O3 is due to its high efficacy in acute promyelocytic leukemia (APL), inducing remissions in over 90% of newly diagnosed or relapsed cases. Most As2O3 preparations are intravenous, although an oral formulation is similarly efficacious. Important side effects include prolongation of QT interval, leucocytosis and the APL differentiation syndrome. Combined use of As2O3 and all trans-retinoic acid (ATRA) has been found to be useful in APL relapsing from previous arsenic-induced remissions. Furthermore, As2O3 + ATRA may give remissions of better quality in newly diagnosed APL. Current research centers on the early introduction of As2O3 in the overall treatment plan of APL, including its use in maintenance therapy after first complete remission. As2O3 has also been used in other hematological malignancies. Of particular promise is the use of As2O3 in multiple myeloma.-
dc.languageeng-
dc.publisherWorld Scientific Publishing Co Pte Ltd. The Journal's web site is located at http://www.worldscinet.com/cr/cr.shtml-
dc.relation.ispartofCancer Reviews: Asia-Pacific-
dc.rightsFor preprints : Preprint of an article published in [Journal, Volume, Issue, Year, Pages] [Article DOI] © [copyright World Scientific Publishing Company] [Journal URL] For postprints : Electronic version of an article published as [Journal, Volume, Issue, Year, Pages] [Article DOI] © [copyright World Scientific Publishing Company] [Journal URL] -
dc.subjectArsenic trioxide-
dc.subjectIntravenous-
dc.subjectOral-
dc.subjectAcute promyelocytic leukemia-
dc.subjectSide effects-
dc.titleArsenates in the treatment of haematological malignancies-
dc.typeArticle-
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0219-8363&volume=2&spage=161&epage=171&date=2004&atitle=Arsenates+in+the+treatment+of+haematological+malignanciesen_HK
dc.identifier.emailKwong, YL: ylkwong@hku.hk-
dc.identifier.authorityKwong, YL=rp00358-
dc.identifier.doi10.1142/S0219836304000469-
dc.identifier.hkuros108028-
dc.identifier.volume2-
dc.identifier.issue2-
dc.identifier.spage161-
dc.identifier.epage171-
dc.publisher.placeSingapore-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats